Physician profile
Brian Adams
NPI 1154796365
$8,279.77
in general payments reported to CMS, 2019-2025
24 companies · $1,097 in 2025
The $1,097 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,489 · 2022: $2,948 · 2023: $1,402 · 2024: $1,344 · 2025: $1,097.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,843.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,842.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,806.21 | 2022-2024 | Venaseal |
| Novartis Pharmaceuticals Corporation | $1,020.52 | 2021-2025 | |
| Boston Scientific Corporation | $1,006.69 | 2021-2025 | Latitude Communicator Power Supply, Lux-Dx Insertable Cardiac Monitor, Accolade Sr |
| Astrazeneca Pharmaceuticals LP | $670.63 | 2021-2025 | Wainua, Farxiga, Lokelma |
| Merck Sharp & Dohme LLC | $663.48 | 2021-2025 | Verquvo, Capvaxive |
| Amgen INC. | $617.00 | 2021-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $590.51 | 2021-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $518.79 | 2021-2025 | Jardiance |
| Pfizer INC. | $241.56 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $207.16 | 2021-2025 | Camzyos, Eliquis |
| Esperion Therapeutics, INC. | $173.08 | 2021-2025 | Nexletol |
| Lexicon Pharmaceuticals, INC. | $156.40 | 2023-2024 | Inpefa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $155.75 | 2021-2023 | Lifevest |
| Terumo Medical Corporation | $87.24 | 2022-2024 | Navicross, Glidesheath Slender |
| Abbott Laboratories | $75.76 | 2021-2025 | Cardiomems |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bridgebio Pharma, INC. | $66.96 | 2025 | Attruby |
| Abiomed | $53.26 | 2025 | |
| Preventice Services, LLC | $41.32 | 2021 | |
| Chiesi USA, INC. | $36.01 | 2021 | |
| Bard Peripheral Vascular, INC. | $23.51 | 2024 | Rotarexs 6 F X 135 Cm |
| Alnylam Pharmaceuticals INC. | $22.70 | 2022 | |
| Angiodynamics, INC. | $19.97 | 2025 | Auryon Laser System 100-120 Vac |
| Amarin Pharma, INC. | $13.01 | 2021 | |
| Itamar Medical INC | $12.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.